Income statement waterfall. Green diagonal stripes add to the running result, red diagonal stripes subtract from it, and a thin axis line marks the loss-zone boundary.
- Revenue: $263.71M. Running result $263.71M. Molecular Profiling Services: $252.25M. Pharma Research And Development Services: $11.46M.
- Cost of revenue: −$84.12M. Running result $179.6M.
- Gross profit: $179.6M. Running result $179.6M.
- Selling and marketing expense: −$53.76M. Running result $125.83M.
- General and administrative expense (see note 9): −$66.55M. Running result $59.28M.
- Research and development expense: −$32.36M. Running result $26.93M.
- Operating income: $26.93M. Running result $26.93M.
- Other expense: −$27.54M. Running result −$614K.
- Pre-tax loss: −$614K. Running result −$614K.
- Income tax expense: −$23K. Running result −$637K.
- Net loss: −$637K. Running result −$637K.
